Plasma rich platelet therapy for hair loss is an increasingly popular minimally invasive treatment in the UK, using growth factors derived from a patient's own blood to support hair follicle activity. As interest grows alongside conventional options such as minoxidil and finasteride, understanding how PRP works, who it suits, what the evidence shows, and how to find a reputable UK clinic is essential. This guide covers the full picture — from the science behind PRP and realistic expectations, to costs, safety considerations, and how to navigate the UK private clinic landscape safely and confidently.

What Is Platelet-Rich Plasma (PRP) Therapy for Hair Loss?

PRP therapy concentrates platelets from a patient's own blood and injects them into the scalp to deliver growth factors that may stimulate hair follicle activity. It is not a licensed medicine in the UK, and preparation standards vary between clinics.

Platelet-rich plasma (PRP) therapy is a minimally invasive, non-surgical treatment that uses components derived from a patient's own blood to encourage hair follicle activity and may help improve hair density in some people experiencing certain types of hair loss. The procedure has gained considerable attention in the UK over recent years as an adjunct to conventional hair loss treatments such as minoxidil or finasteride.

Not sure if this is normal? Chat with one of our pharmacists →

PRP is prepared by drawing a small volume of the patient's blood — volumes vary by protocol, typically in the range of 10–20 ml — and processing it in a centrifuge to separate and concentrate the platelet-rich fraction from red blood cells and platelet-poor plasma. The resulting preparation contains a higher concentration of platelets than whole blood. It is important to note that there is no universally agreed preparation standard; centrifuge speed, platelet concentration, and activation methods differ between clinics and commercial systems.

Platelets are rich in growth factors, including:

• Platelet-derived growth factor (PDGF)

• Vascular endothelial growth factor (VEGF)

• Transforming growth factor-beta (TGF-β)

• Insulin-like growth factor (IGF)

These growth factors are believed to stimulate dormant or weakened hair follicles, promoting a return to the active (anagen) phase of the hair growth cycle. The precise mechanisms remain an active area of research.

Regulatory status: Autologous PRP is not a licensed medicinal product or an Advanced Therapy Medicinal Product (ATMP) regulated by the MHRA. However, the kits and systems used to prepare PRP are medical devices and must carry UKCA or CE marking in accordance with MHRA requirements. Patients should ensure they receive treatment from appropriately trained, registered healthcare professionals using appropriately marked, single-use equipment with robust infection prevention measures in place.

In England, clinics providing treatment of a disease, disorder, or injury may be required to register with the Care Quality Commission (CQC). Patients are advised to verify that their chosen provider holds the appropriate registration. If you experience a suspected side effect or problem related to a device used during PRP treatment, you can report this to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

How PRP Treatment Works to Stimulate Hair Growth

PRP delivers concentrated growth factors to dermal papilla cells in the scalp, potentially prolonging the anagen (growth) phase and improving blood supply to follicles. It does not reverse the underlying genetic or hormonal causes of androgenetic alopecia.

The mechanism by which PRP may support hair regrowth centres on the concentrated delivery of growth factors directly into the scalp at the level of the hair follicle. When injected into the dermis of the scalp, these bioactive proteins are thought to interact with follicular stem cells and dermal papilla cells — the specialised cells that govern the hair growth cycle. It is important to emphasise that these mechanisms are supported primarily by preclinical studies and small clinical trials; the evidence in humans remains evolving and not all aspects of PRP's action on hair follicles are fully understood.

The dermal papilla plays a critical role in regulating the transition between the anagen (growth), catagen (transition), and telogen (resting) phases of the hair cycle. In conditions such as androgenetic alopecia (male and female pattern hair loss), follicles progressively miniaturise and spend longer periods in the telogen phase. The growth factors delivered via PRP are hypothesised to:

• Promote angiogenesis — the formation of new blood vessels — potentially improving nutrient supply to follicles

• Stimulate proliferation of dermal papilla cells

• Prolong the anagen phase, encouraging thicker, longer hair strands

• Reduce follicular inflammation, which may contribute to miniaturisation

VEGF in particular is thought to support the development of a richer capillary network around the follicle, which may enhance the delivery of oxygen and nutrients essential for healthy hair production. These proposed effects are plausible based on available data but should not be regarded as definitively established.

PRP does not reverse the underlying genetic or hormonal drivers of androgenetic alopecia. Rather, it is thought to create a more favourable biological environment for follicles that retain some residual function. This is why the treatment is generally considered more likely to be of benefit in earlier stages of hair loss, where viable follicles are still present, and is unlikely to produce results where follicles are completely absent.

Who May Be Suitable for PRP Hair Loss Treatment in the UK

PRP is most suitable for adults with early to moderate androgenetic alopecia who still have viable follicles; it is contraindicated in those on anticoagulants, with active scalp infections, thrombocytopenia, or active cancer. Underlying reversible causes of hair loss should be excluded before treatment.

PRP therapy is not appropriate for every individual experiencing hair loss, and a thorough clinical assessment is essential before proceeding. In the UK, reputable practitioners will conduct a detailed consultation to determine whether PRP is a suitable option based on the type, cause, and extent of hair loss.

Conditions for which PRP may be considered include:

• Androgenetic alopecia (male and female pattern baldness) — the most common indication, with the most supportive evidence

• Alopecia areata — an autoimmune condition causing patchy hair loss; evidence is limited and inconsistent, and first-line treatments differ

• Telogen effluvium — diffuse shedding often triggered by stress, illness, or nutritional deficiency; evidence for PRP in this condition is very limited, and as telogen effluvium is usually self-limiting, identifying and treating the underlying cause should always be the priority

PRP is generally considered most likely to be of benefit for individuals in the early to moderate stages of hair loss, where follicles are miniaturised but not completely absent. Advanced baldness with complete follicle loss is unlikely to respond to PRP.

Contraindications and cautions include:

• Active scalp infections or inflammatory skin conditions

• Thrombocytopenia or platelet dysfunction

• Anticoagulant therapy (e.g., warfarin) or antiplatelet therapy — do not stop any prescribed medication without first seeking medical advice

• Active cancer or recent chemotherapy

• Pregnancy

• Uncontrolled systemic disease (e.g., poorly controlled diabetes)

• Keloid tendency

• Certain autoimmune conditions

Red flags — seek GP or dermatology assessment promptly if you notice:

• Rapid or widespread hair loss

• Scalp pain, scaling, pustules, or scarring (which may suggest scarring alopecia requiring urgent specialist review)

• Nail changes alongside hair loss

• Signs of hyperandrogenism in women (e.g., irregular menstrual cycles, hirsutism)

• Hair loss in children or adolescents

Before treatment, practitioners should take a thorough medical history and may recommend baseline blood tests to exclude underlying causes of hair loss. Tests may include a full blood count (FBC), serum ferritin, thyroid-stimulating hormone (TSH), and vitamin B12 or vitamin D where clinically indicated. Reversible causes — such as iron deficiency, thyroid dysfunction, or nutritional deficiency — should be identified and treated before pursuing procedural interventions. NICE Clinical Knowledge Summaries (CKS) and British Association of Dermatologists (BAD) patient information leaflets provide further guidance on assessment and referral pathways. Patients are encouraged to speak with their GP if they notice sudden or rapidly progressive hair loss.

What to Expect During and After a PRP Session

A PRP session takes 60–90 minutes and involves blood draw, centrifugation, and scalp injections under topical anaesthetic; common after-effects include temporary redness, swelling, and mild tenderness resolving within 24–48 hours. Seek urgent medical attention if signs of infection develop.

A typical PRP session for hair loss is performed in a clinical setting and usually takes between 60 and 90 minutes from start to finish. Understanding the process can help patients make an informed decision and manage expectations appropriately.

1. The procedure generally follows these steps:
2. A small blood sample is drawn from the patient's arm
3. The blood is placed in a centrifuge and spun to separate the platelet-rich plasma
4. The scalp is cleansed and, in most cases, a topical anaesthetic cream is applied to minimise discomfort
5. The PRP is injected into targeted areas of the scalp using a fine needle, typically at 1–2 cm intervals

Most patients describe the injections as mildly uncomfortable rather than painful, particularly once the anaesthetic has taken effect.

Common post-procedure effects include:

• Temporary redness, swelling, or tenderness at injection sites

• Mild bruising or a sensation of tightness on the scalp

• Occasional headache in the hours following treatment

• Temporary increase in hair shedding in the weeks following treatment (this is usually transient)

These effects typically resolve within 24–48 hours.

Rarer but important risks include: infection at injection sites, vasovagal episodes (feeling faint during or after the procedure), reactions to local anaesthetic, and, very rarely, neurovascular injury or scarring. Patients should discuss the full risk profile with their practitioner before consenting to treatment.

Aftercare: Patients are generally advised to avoid washing their hair for 24 hours, refrain from vigorous exercise for 48 hours, and avoid hair dyes, chemical treatments, saunas, and swimming for 48–72 hours following treatment, in line with their clinic's protocol. Some practitioners advise avoiding anti-inflammatory medications such as ibuprofen for several days after treatment on the basis that these may theoretically interfere with platelet activity; however, this advice is precautionary and not supported by robust evidence. Patients must not stop any prescribed antiplatelet, anticoagulant, or anti-inflammatory medication without first seeking advice from their GP or prescriber.

Seek urgent medical attention if you develop signs of infection such as increasing pain, spreading redness, warmth, swelling, discharge from injection sites, or fever.

A course of treatment typically involves three to four sessions spaced four to six weeks apart, followed by maintenance sessions every three to six months, though it is important to note that treatment schedules are not standardised and vary between practitioners and protocols. Results are gradual; most patients begin to notice reduced shedding after the first few sessions, with any visible improvements in hair density typically emerging over three to six months. Individual responses vary considerably.

Effectiveness and Evidence: What the Research Shows

Systematic reviews and meta-analyses report significant improvements in hair density with PRP for androgenetic alopecia, but evidence quality is limited by small studies, lack of standardisation, and short follow-up periods. There is no NICE recommendation for PRP, and it is not considered a standard of care.

The evidence base for PRP in hair loss treatment has grown over the past decade, though the overall quality of evidence remains moderate, and further large-scale, well-controlled trials are needed before definitive conclusions can be drawn.

A number of systematic reviews and meta-analyses have reported statistically significant improvements in hair density, hair count, and hair thickness following PRP treatment, particularly in androgenetic alopecia. A 2019 systematic review published in Aesthetic Plastic Surgery found that the majority of included studies reported positive outcomes, with PRP demonstrating superiority over placebo in several randomised controlled trials. A 2020 meta-analysis published in the Journal of the American Academy of Dermatology concluded that PRP significantly increased hair density compared with control groups. However, effect sizes varied considerably across studies, and the clinical significance of improvements reported in some trials remains uncertain.

Important limitations in the current evidence include:

• Lack of standardisation in PRP preparation protocols (centrifuge speed, platelet concentration, activation methods, injection technique), making direct comparison between studies difficult

• Small sample sizes in many studies

• Short follow-up periods, making long-term efficacy and durability of effect difficult to assess

• Variability in outcome measures across studies

• Heterogeneity in patient populations and hair loss severity

For alopecia areata, evidence is more preliminary and inconsistent; first-line treatments recommended by dermatologists differ from PRP. For telogen effluvium, evidence is very limited and PRP is not generally recommended; treating the underlying cause remains the priority.

There is currently no NICE guidance specifically recommending PRP for hair loss, and it is not routinely available on the NHS. The treatment is considered an emerging adjunct therapy rather than an established standard of care. PRP appears most promising when used alongside evidence-based treatments such as topical minoxidil or, where appropriate, finasteride, but it is not a cure for hair loss.

Patients should approach claims of guaranteed results with caution. Realistic expectations and transparent communication from the treating practitioner are essential. The BAD may publish position statements or guidance on PRP use; patients are encouraged to consult their website for the most current information.

Costs, Availability, and Finding a Reputable UK Clinic

PRP for hair loss is available only privately in the UK, typically costing £200–£600 per session or £600–£2,000 for an initial course. Patients should verify practitioner registration with the GMC, NMC, or HCPC and confirm CQC registration for the clinic in England.

PRP therapy for hair loss is not routinely available on the NHS and is offered through private clinics across the UK. Even if accessing PRP privately, patients are encouraged to speak with their GP first, who can help exclude underlying medical causes of hair loss and, if appropriate, provide a referral to a consultant dermatologist for an independent assessment.

Typical costs in the UK:

• A single PRP session generally ranges from £200 to £600

• An initial course of three to four sessions may cost between £600 and £2,000

• Ongoing maintenance sessions represent an additional recurring expense

Prices vary depending on the clinic's location (London-based clinics typically charge more), the practitioner's qualifications, and the technology used. Patients should be wary of unusually low prices, which may reflect inferior equipment or inadequately trained practitioners, and equally wary of clinics making claims of guaranteed results, which are not supported by the evidence and may breach Advertising Standards Authority (ASA) and Committee of Advertising Practice (CAP) guidelines on cosmetic intervention advertising.

When choosing a clinic, patients are advised to:

• Verify the practitioner's registration — ideally a doctor, nurse, or allied health professional registered with the GMC, NMC, or HCPC respectively

• Check CQC registration (in England) where the clinic provides treatment of a disease, disorder, or injury

• Confirm that UKCA or CE-marked, single-use PRP preparation kits are used and that robust infection prevention measures are in place

• Request a thorough consultation before committing to treatment, including a discussion of risks, realistic outcomes, and alternatives

• Ensure written informed consent is obtained and that you are given adequate time to consider your decision before proceeding

• Ask about the clinic's indemnity insurance and complaints procedure

• Be appropriately sceptical of before-and-after photographs and marketing claims

Organisations and resources that may help patients identify qualified specialists include:

• British Association of Dermatologists (BAD) — specialist directory and patient information

• British Hair and Nail Society (BHNS) — UK specialist directory for hair disorders

• Joint Council for Cosmetic Practitioners (JCCP) and Save Face — voluntary registers of trained and insured aesthetic practitioners

If in doubt, patients are encouraged to speak with their GP, who can offer guidance on the most appropriate treatment pathway for their individual circumstances.

Frequently Asked Questions